Allan Bohm1,2,3, Lubos Urban4, Lubomira Tothova5,6, Ljuba Bacharova6,7, Peter Musil6, Jan Kyselovic6, Peter Michalek8,6, Tomas Uher8, Branislav Bezak4,6, Peter Olejnik4,6, Robert Hatala4,9. 1. National Institute of Cardiovascular Diseases, Pod Krasnou horkou 1, SK-83348, Bratislava, Slovakia. allan.bohm@gmail.com. 2. 3rd Department of Internal Medicine, University Hospital Bratislava, Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia. allan.bohm@gmail.com. 3. Premedix Academy, Bratislava, Slovakia. allan.bohm@gmail.com. 4. National Institute of Cardiovascular Diseases, Pod Krasnou horkou 1, SK-83348, Bratislava, Slovakia. 5. Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia. 6. Faculty of Medicine, Comenius University, Bratislava, Slovakia. 7. International Laser Center, Bratislava, Slovakia. 8. Premedix Academy, Bratislava, Slovakia. 9. Faculty of Medicine, Slovak Medical University, Bratislava, Slovakia.
Abstract
PURPOSE: Oxidative stress is an important contributor to the etiology of atrial fibrillation (AF). Our aim was to study oxidative stress biomarkers in patients undergoing pulmonary vein isolation (PVI) for paroxysmal AF with radiofrequency catheter ablation and to assess its prognostic value in predicting long-term PVI outcome. METHODS: In this prospective cohort study, we included 62 patients (mean age 55±8 years, 12 females and 50 males) with paroxysmal AF and implanted ECG loop recorders who underwent PVI. Plasmatic concentrations of advanced glycation end-products (AGEs), fructosamine, advanced oxidation protein products, and thiobarbituric-acid reacting substances were measured before PVI. AF burden (percentage of time spent in AF) was continually assessed during the follow-up period (1063±271 days). RESULTS: Nineteen patients (31%) were defined as optimal responders (oR) with AF burden < 0.5% after PVI. Remaining 43 patients (69%) were defined as sub-optimal responders. Concentration of AGEs was significantly lower in oR by 3.7 g/g (CI: -6.5 to -1.7; P=0.0003). After adjustment for age, sex, BMI, left atrial size, arterial hypertension, and AF burden before PVI, only low concentration of AGEs remained significantly associated with oR (odds ratio: 1.3; P=0.04). AGEs concentration achieved area under the curve of 0.78 for predicting optimal long-term PVI response. CONCLUSIONS: AGEs concentration before PVI was associated with long-term PVI outcome in patients with paroxysmal AF. Further research will show if this biomarker could contribute to optimal patient selection for catheter ablation.
PURPOSE: Oxidative stress is an important contributor to the etiology of atrial fibrillation (AF). Our aim was to study oxidative stress biomarkers in patients undergoing pulmonary vein isolation (PVI) for paroxysmal AF with radiofrequency catheter ablation and to assess its prognostic value in predicting long-term PVI outcome. METHODS: In this prospective cohort study, we included 62 patients (mean age 55±8 years, 12 females and 50 males) with paroxysmal AF and implanted ECG loop recorders who underwent PVI. Plasmatic concentrations of advanced glycation end-products (AGEs), fructosamine, advanced oxidation protein products, and thiobarbituric-acid reacting substances were measured before PVI. AF burden (percentage of time spent in AF) was continually assessed during the follow-up period (1063±271 days). RESULTS: Nineteen patients (31%) were defined as optimal responders (oR) with AF burden < 0.5% after PVI. Remaining 43 patients (69%) were defined as sub-optimal responders. Concentration of AGEs was significantly lower in oR by 3.7 g/g (CI: -6.5 to -1.7; P=0.0003). After adjustment for age, sex, BMI, left atrial size, arterial hypertension, and AF burden before PVI, only low concentration of AGEs remained significantly associated with oR (odds ratio: 1.3; P=0.04). AGEs concentration achieved area under the curve of 0.78 for predicting optimal long-term PVI response. CONCLUSIONS: AGEs concentration before PVI was associated with long-term PVI outcome in patients with paroxysmal AF. Further research will show if this biomarker could contribute to optimal patient selection for catheter ablation.
Authors: Hugh Calkins; Karl Heinz Kuck; Riccardo Cappato; Josep Brugada; A John Camm; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; John DiMarco; James Edgerton; Kenneth Ellenbogen; Michael D Ezekowitz; David E Haines; Michel Haissaguerre; Gerhard Hindricks; Yoshito Iesaka; Warren Jackman; Jose Jalife; Pierre Jais; Jonathan Kalman; David Keane; Young-Hoon Kim; Paulus Kirchhof; George Klein; Hans Kottkamp; Koichiro Kumagai; Bruce D Lindsay; Moussa Mansour; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Douglas L Packer; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Vivek Reddy; Jeremy N Ruskin; Richard J Shemin; Hsuan-Ming Tsao; David Wilber Journal: Europace Date: 2012-03-01 Impact factor: 5.214
Authors: E Kevin Heist; Fadi Chalhoub; Conor Barrett; Stephan Danik; Jeremy N Ruskin; Moussa Mansour Journal: Am J Cardiol Date: 2012-05-15 Impact factor: 2.778
Authors: Ethan M Balk; Ann C Garlitski; Alawi A Alsheikh-Ali; Teruhiko Terasawa; Mei Chung; Stanley Ip Journal: J Cardiovasc Electrophysiol Date: 2010-11
Authors: Christos A Goudis; Panagiotis Korantzopoulos; Ioannis V Ntalas; Eleftherios M Kallergis; Dimitrios G Ketikoglou Journal: J Cardiol Date: 2015-05-07 Impact factor: 3.159